Phaseline

Targets › GNRHR

GNRHR (Gonadotropin-releasing hormone receptor): drug programs, companies and trials

78 programs from 63 companies in 132 trials: 68 Phase 2, 36 Phase 3, 18 Phase 4, 10 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30968)

Open in Phaseline: the race on GNRHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Turku University HospitalDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 4Prostatic Hyperplasia; Localized Prostate CarcinomaDec 2026
Li-jun DingTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4Deep Infiltrating Endometriosis (DIE)Dec 2026
Aristotle University Of ThessalonikiGoserelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4Metabolic Dysfunction-Associated Steatotic Liver DiseaseApr 2027
University Reproductive AssociatesGonadorelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4InfertilityJul 2027
University of Delawareganirelix acetate
GnRH receptor antagonist
GNRHRPhase 4EstrogenOct 2027
HanAll BioPharmaLeuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4CPPNov 2027
Fundacion DexeusIntranasal nafarelin
GnRH receptor agonist
GNRHRPhase 4Fertility PreservationJan 2028
University of Colorado, DenverDegarelix Acetate
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 4MenopauseMay 2028
LG ChemLeuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4Central Precocious Puberty; Prostate Cancer; Androgen Deprivation Therapy; Advanced Salivary Gland Carcinoma …Aug 2029
Gangnam Severance HospitalGoserelin acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4Breast CancerJan 2031
Gangnam Severance HospitalLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 4Breast CancerJan 2031
Qilu PharmaceuticalRelugolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Heavy Menstrual Bleeding; Cervical Mucus; Endometriosis; Recurrent Prostate Carcinoma …Nov 2026
Ottawa Hospital Research InstituteLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerNov 2026
Fundación para la Investigación del Hospital Clínico de ValenciaTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Low Ovarian ReserveJul 2027
AbbVieElagolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Endometriosis; Menopause; InfertilityJul 2027
PfizerLeuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Hormone Sensitive Prostate CancerJul 2027
UNICANCERLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3MetastasesSep 2027
Assistance Publique - Hôpitaux de ParisTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3In Vitro FertilizationSep 2027
Kissei PharmaceuticalLinzagolix (KLH-2109)
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3EndometriosisNov 2027
Proton Collaborative Groupbuserelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerDec 2027
Proton Collaborative Grouptriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerDec 2027
Kenny Rodriguez-WallbergTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Breast Cancer FemaleJan 2028
JW PharmaceuticalLinzagolix (KLH-2109)
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3MenorrhagiaMar 2028
Sumitomo Pharma SwitzerlandRelugolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Uterine FibroidsJul 2029
Children's Oncology GroupTriptorelin Pamoate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Hematopoietic and Lymphatic System NeoplasmOct 2029
Marco Lorenzo BonuTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerDec 2029
Alliance for Clinical Trials in Oncologygoserelin acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerOct 2030
Alliance for Clinical Trials in Oncologyleuprolide acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerOct 2030
Radiation Therapy Oncology GroupLuteinizing hormone-releasing hormone (LHRH) agonist or antagonist
LHRH receptor agonist or antagonist - suppresses testosterone production
GNRHRPhase 3Prostate CancerJul 2031
NRG OncologyGnRH agonist
GnRH receptor agonist - suppresses ovarian function
GNRHRPhase 3Breast CancerJan 2032
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápictriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Prostate CancerDec 2032
SWOG Cancer Research NetworkDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Castration Levels of TestosteroneApr 2033
European Organisation for Research and Treatment of Cancer - EORTCDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Prostate Cancer–
Changchun GeneScience PharmaceuticalLeuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Breast Cancer Subjects–
The University of Hong KongTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Subfertility–
Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Endometriosis–
National Cancer Institute (NCI)Leuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Locally Advanced Salivary Gland CarcinomaNov 2026
National Taiwan University HospitalGoserelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Triple Negative Breast CancerDec 2026
Fudan UniversityLHRH agonist or antagonist
Luteinizing hormone-releasing hormone receptor agonist/antagonist
GNRHRPhase 2Metastatic Prostate CancerDec 2026
McGill University Health Centre/Research Institute of the McGill University Health CentreLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate CancerDec 2026
National Taiwan University HospitalLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Triple Negative Breast CancerDec 2026
Memorial Sloan Kettering Cancer CenterLeuprolide acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Leukemia; Prostate CancerDec 2026
SOLTI Breast Cancer Research GroupTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Breast CancerDec 2026
National Taiwan University HospitalTriptorelin pamoate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Triple Negative Breast CancerDec 2026
Jonsson Comprehensive Cancer CenterLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Metastatic Prostate AdenocarcinomaJan 2027
City of Hope Medical CenterDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Prostate AdenocarcinomaJan 2027
City of Hope Medical CenterGoserelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate Adenocarcinoma; PSA Level Greater Than TwoJan 2027
City of Hope Medical CenterLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate Adenocarcinoma; PSA Level Greater Than TwoJan 2027
Regina Elena Cancer InstituteTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate CancerFeb 2027
Bedaya HospitalCetrorelix acetate
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2InfertilityMar 2027
Fudan UniversityTriprorelin Acetate
Gonadotropin-releasing hormone agonist (GnRHa)
GNRHRPhase 2Endometrial Neoplasm Malignant Stage IMar 2027
Jose Pablo LeoneDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Male Breast CancerApr 2027
Sir Mortimer B. Davis - Jewish General HospitalGoserelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Castration-resistant Prostate Cancer Patients with OligometastasesApr 2027
Sir Mortimer B. Davis - Jewish General HospitalLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Castration-resistant Prostate Cancer Patients with OligometastasesApr 2027
Sir Mortimer B. Davis - Jewish General HospitalTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Castration-resistant Prostate Cancer Patients with OligometastasesApr 2027
Ottawa Hospital Research InstituteTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostatic NeoplasmsJun 2027
Martin Blomberg JensenTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Menopausal OsteoporosisDec 2027
Fudan UniversityTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Endometrial CancerDec 2027
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate Cancer Metastatic DiseaseDec 2027
Xiaojun ChenGnRHa (Triprorelin acetate)
Gonadotropin-releasing hormone analogue
GNRHRPhase 2Endometrial NeoplasmsMar 2028
NYU Langone HealthDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Prostate CancerAug 2028
Nelly PitteloudGnRH, gonadorelin acetate
GnRH receptor agonist; pulsatile GnRH acts on GNRHR in the pituitary gland to stimulate LH
GNRHRPhase 2Down SyndromeDec 2028
Mayo ClinicGoserelin Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Anatomic Stage I Breast Cancer AJCC v8Dec 2028
Seoul National University HospitalLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Breast CancerDec 2028
VA Office of Research and DevelopmentDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Prostate CancerMar 2029
Memorial Sloan Kettering Cancer CenterDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Prostate CancerJan 2030
Baptist Health South FloridaDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Prostate CancerFeb 2030
Baptist Health South FloridaTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate CancerFeb 2030
Universitaire Ziekenhuizen KU LeuvenTriptoreline
GnRH receptor agonist (androgen deprivation therapy)
GNRHRPhase 2Prostate CancerFeb 2031
Ontario Clinical Oncology Group (OCOG)Leuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Prostate AdenocarcinomaApr 2031
UNICANCERDegarelix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 2Adenocarcinoma of Prostate–
Hopital FochTriptorelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 2Endometriosis–
AmgenGnRH Antagonist
Gonadotropin-releasing hormone antagonist
GNRHRPhase 1Prostate Cancer; Atypical Endometrial Hyperplasia; Endometrial NeoplasmsFeb 2027
TerSera TherapeuticsGoserelin
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 1Advanced Breast Cancer; Musculoskeletal Injury; Prostate Cancer; Breast Cancer …Mar 2027
Zhuhai Huahaikang Pharmaceutical TechnologyHHK001
GnRH receptor agonist (leuprorelin acetate)
GNRHRPhase 1EndometriosisMar 2027
Roswell Park Cancer InstituteLeuprolide Acetate
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 1Castration-Resistant Prostate CarcinomaMar 2028
Peter Busch ØstergrenADT (gonadotropin-releasing hormone antagonist or agonist)
Gonadotropin-releasing hormone antagonist or agonist for medical castration
GNRHRPhase 1Prostate Cancer MetastaticOct 2028
The Affiliated Hospital of Qingdao UniversityTriprorelin for injection
GnRH receptor agonist
GNRHRPhase 1Prostate Cancer (CRPC)–

Conditions

Prostate Cancer (39) Prostate Adenocarcinoma (7) Endometriosis (7) Breast Cancer (7) Menopause (4) Anatomic Stage I Breast Cancer AJCC v8 (3) Infertility (3) Castration-resistant Prostate Cancer Patients with Oligometastases (3) Triple Negative Breast Cancer (3) Androgen Deprivation Therapy (2) Tubular Breast Cancer (2) PSA Level Greater Than Two (2)

Modalities

small molecule (71), mixed (4), protein or peptide (2)

Companies

Fudan University (3) City of Hope Medical Center (3) Sir Mortimer B. Davis - Jewish General Hospital (3) National Taiwan University Hospital (3) UNICANCER (2) Baptist Health South Florida (2) Proton Collaborative Group (2) Memorial Sloan Kettering Cancer Center (2) Ottawa Hospital Research Institute (2) Gangnam Severance Hospital (2) Alliance for Clinical Trials in Oncology (2) LG Chem (1) Assistance Publique - Hôpitaux de Paris (1) Universitaire Ziekenhuizen KU Leuven (1) JW Pharmaceutical (1) The University of Hong Kong (1) Martin Blomberg Jensen (1) European Organisation for Research and Treatment of Cancer - EORTC (1) Rumah Sakit Pusat Angkatan Darat Gatot Soebroto (1) SOLTI Breast Cancer Research Group (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.